Search
Junshi Biosciences' wholly-owned subsidiary, Juntao Biosciences, has recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration (NMPA), marking the approval of its application for clinical trials of JT118 Injection. JT118 is an innovative "two-in-one" recombinant protein vaccine, formulated through the tandem fusion of monkeypox virus antigens A35 and M1, specifically designed to prevent infections caused by the monkeypox virus. Currently, no vaccine against monkeypox virus infection has been authorized for marketing within China. Given the inherent uncertainties associated with the extended drug development cycle and the multitude of approval processes involved, Junshi Biosciences cautions investors to make prudent decisions and remain vigilant of potential investment risks.
-
C114 Communication Network -
Communication Home
